Avacta plc (LON:AVCT) CEO Alastair Smith joins DirectorsTalk to discuss an agreement with ADC therapeutics. Alastair talks us through the agreement, explains what is expected from AVA6000 pro-doxorubicin in the phase
Avacta Group (LON:AVCT), the developer of Affimer® biotherapeutics and research reagents, is pleased to announce a proposed Placing and Subscription to raise gross proceeds of up to £9 million through the issuance of
Avacta Group (LON:AVCT), the developer of Affimer® biotherapeutics and research reagents, announced its unaudited interim results for the 12 months ended 31 July 2019. Operating highlights Affimer Therapeutics · Major validating partnership and license
Affmer proteins are recombinant affinity reagents that exhibit high affinity and high specificity binding across a range of reaction conditions. The rapid in vitro screening process for Affimer binder identification
Avacta Group (LON:AVCT) has entered into an agreement with ADC Therapeutics SA (Lausanne CH) under which the parties will develop jointly Affimer-drug conjugates combining Avacta’s Affimer® technology with ADC Therapeutics’
Avacta Group (LON:AVCT), (Cambridge and Wetherby UK), a biotechnology company developing novel cancer immunotherapies based on its proprietary Affimer® platform, today announced that it has entered a collaboration and option agreement with ADC
Affimer reagents have been successfully used to detect and quantify antigens across a broad range of immunoassay platforms. Highly specific Affimer binders can be generated to a wide variety of
Avacta will once again be presenting and exhibiting (Booth 10) at the Biomarkers and Precision Medicine Congress (8th and 9th October) in San Diego, CA. “Using complex-specific Affimer affinity reagents to
Therapeutic antibodies are the fastest growing class of drugs in the treatment of cancer, and autoimmune and inflammatory diseases that require the concomitant development of assays to monitor therapeutic antibody
“The sad fact is that around 70% of cancer patients with solid based tumors don’t respond to classical chemotherapy,” said Joseph Tabernero, MD, PhD, head of Val d’Hebron Institute of
© 2024 – DirectorsTalk. All rights reserved. Reproduction in whole or in part, in any form or medium without express written permission is prohibited.
